Filing Flows › Xilio Therapeutics (XLO) › Q1 2026
Xilio Therapeutics (XLO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Xilio Therapeutics (XLO) reported revenue of $12.6M for the first quarter 2026 (Q1 2026), +332% from a year earlier and -8% from the quarter before. Operating margin was -111.6%, net loss $9.5M (75.3% of revenue).
Xilio Therapeutics, Q1 2026: revenue $12.6M (+332% year over year), operating margin -111.6%, net loss $9.5M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.6M | -8% | +332% |
| Operating profit | −$14.1M | — | — |
| Net earnings | −$9.5M | -192% | — |
| Operating cash flow | −$22.3M | — | -177% |
What changed
Revenue was $12.6M in Q1 2026, up 332% year over year and down 8% from the previous quarter.
Operating costs exceeded revenue by $14.1M, an operating margin of -111.6%. Total costs grew 59% against revenue growth of 332%. The fastest-growing cost line was Research & development (+140%). The quarter ended with a net loss of $9.5M, after a profit of $10.4M the previous quarter. Non-operating items added $4.6M, -48% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$22.3M. Non-cash charges added back $344K of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items used $15.4M. Capital expenditures of $556K exceeded it, leaving free cash flow of −$22.9M.
Questions
What was Xilio Therapeutics' revenue in the first quarter 2026?
Xilio Therapeutics (XLO) reported revenue of $12.6M for the first quarter 2026 (Q1 2026), +332% from a year earlier and -8% from the quarter before.
Was Xilio Therapeutics profitable in the first quarter 2026?
Operating loss was $14.1M (-111.6% of revenue) and net loss $9.5M.
Source: Xilio Therapeutics 10-Q on SEC EDGAR.